These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9309153)

  • 1. [Development of new antitumor reagents which block the cell cycle progression].
    Osada H
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1541-6. PubMed ID: 9309153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
    Kaubisch A; Schwartz GK
    Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53.
    Park MJ; Kim EH; Park IC; Lee HC; Woo SH; Lee JY; Hong YJ; Rhee CH; Choi SH; Shim BS; Lee SH; Hong SI
    Int J Oncol; 2002 Aug; 21(2):379-83. PubMed ID: 12118335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
    McInnes C
    Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest.
    Patel V; Lahusen T; Sy T; Sausville EA; Gutkind JS; Senderowicz AM
    Cancer Res; 2002 Mar; 62(5):1401-9. PubMed ID: 11888912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [G1 block of the cell cycle during differentiation of F9 cells correlates with accumulation of inhibitors of the activity of cyclin-kinase complexes of proteins p21/Waf1 and p27/Kip].
    Malashicheva AB; Kisliakova TV; Pospelov VA
    Tsitologiia; 2002; 44(7):649-55. PubMed ID: 12455373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cyclin D1 expression and phosphorylation of retinoblastoma protein by phosmidosine, a nucleotide antibiotic.
    Kakeya H; Onose R; Liu PC; Onozawa C; Matsumura F; Osada H
    Cancer Res; 1998 Feb; 58(4):704-10. PubMed ID: 9485024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclins and related kinases in cancer cells.
    Malumbres M
    J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
    Fischer PM
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
    Chang YT; Gray NS; Rosania GR; Sutherlin DP; Kwon S; Norman TC; Sarohia R; Leost M; Meijer L; Schultz PG
    Chem Biol; 1999 Jun; 6(6):361-75. PubMed ID: 10375538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioprobes for investigating mammalian cell cycle control.
    Osada H
    J Antibiot (Tokyo); 1998 Nov; 51(11):973-82. PubMed ID: 9918389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
    Abate AA; Pentimalli F; Esposito L; Giordano A
    Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early development of cyclin dependent kinase modulators.
    Roy KK; Sausville EA
    Curr Pharm Des; 2001 Nov; 7(16):1669-87. PubMed ID: 11562305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.
    Vermeulen K; Van Bockstaele DR; Berneman ZN
    Cell Prolif; 2003 Jun; 36(3):131-49. PubMed ID: 12814430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors.
    Nugiel DA; Etzkorn AM; Vidwans A; Benfield PA; Boisclair M; Burton CR; Cox S; Czerniak PM; Doleniak D; Seitz SP
    J Med Chem; 2001 Apr; 44(9):1334-6. PubMed ID: 11311054
    [No Abstract]   [Full Text] [Related]  

  • 19. Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future.
    Haesslein JL; Jullian N
    Curr Top Med Chem; 2002 Sep; 2(9):1037-50. PubMed ID: 12171570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatases as targets for cancer treatment.
    Lazo JS; Wipf P
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1297-304. PubMed ID: 19943201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.